Please use this identifier to cite or link to this item:
|Title:||225Ac-PSMA617: PSMA targeting alpha-radiation therapy of patients with mCRPC|
|Authors:||KRATOCHWIL CLEMENS; BRUCHERTSEIFER FRANK; GIESEL FREDERIK; APOSTOLIDIS CHRISTOS; HABERKORN UWE; MORGENSTERN ALFRED|
|Publisher:||European Commission - Joint Research Centre|
|Type:||Articles in periodicals and books|
|Abstract:||To evaluate the potential of PSMA targeting 225Ac-PSMA617 as a promising new treatment option for poor prognosis advanced stage mCRPC (metastatic castration-resistant prostate cancer) patients. An appropriate starting activity for clinical application of 225Ac-PSMA617 was defined by preliminary dosimetry modeling. The treatment protocol was further refined by an empirical dose escalation during “compassionate use” in a first group of advanced stage patients. The derived “standard operation procedure” was used to treat a larger group of patients, which now has >6 months of follow up. Here we report our clinical observations in regard to anti-tumor activity as well as acute and mid-term toxicities experienced with this new concept of mCRPC therapy.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.